Company / Current Liabilities
Serina Therapeutics, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$3.6M
FY2025
5-year range
$1.4M / $10.1M
FY2021-FY2025
Trend
+50.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $1M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -7.8%.
Increased from $1M to $4M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -29.3%
- 5-Year CAGR
- -7.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -7.8%, indicating a declining trend.
- In FY2025, current liabilities increased 50.6% year-over-year.
- Peak current liabilities was recorded in FY2022.
- Lowest current liabilities in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.6M | +50.6% |
| FY2024 | $2.4M | +67.4% |
| FY2023 | $1.4M | -86.0% |
| FY2022 | $10.1M | +12.4% |
| FY2021 | $9.0M | +67.4% |
| FY2020 | $5.4M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026